Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The co-inhibitory receptor Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) attenuates immune responses and prevent autoimmunity, however, tumors exploit this pathway to evade the host T-cell response. The T-cell co-stimulatory receptor 4-1BB is transiently upregulated on T-cells following activation and increases their proliferation and inflammatory cytokine production when engaged. Antibodies which block CTLA-4 or which activate 4-1BB can promote the rejection of some murine tumors, but fail to cure poorly immunogenic tumors like B16 melanoma as single agents. METHODOLOGY/PRINCIPAL FINDINGS: We find that combining αCTLA-4 and α4-1BB antibodies in the context of a Flt3-ligand, but not a GM-CSF, based B16 melanoma vaccine promoted synergistic levels of tumor rejection. 4-1BB activation elicited strong infiltration of CD8+ T-cells into the tumor and drove the proliferation of these cells, while CTLA-4 blockade did the same for CD4+ effector T-cells. Anti-4-1BB also depressed regulatory T-cell infiltration of tumors. 4-1BB activation strongly stimulated inflammatory cytokine production in the vaccine and tumor draining lymph nodes and in the tumor itself. The addition of CTLA-4 blockade further increased IFN-γ production from CD4+ effector T-cells in the vaccine draining node and the tumor. Anti 4-1BB treatment, with or without CTLA-4 blockade, induced approximately 75% of CD8+ and 45% of CD4+ effector T-cells in the tumor to express the killer cell lectin-like receptor G1 (KLRG1). Tumors treated with combination antibody therapy showed 1.7-fold greater infiltration by these KLRG1+CD4+ effector T-cells than did those treated with α4-1BB alone. CONCLUSIONS/SIGNIFICANCE: This study shows that combining T-cell co-inhibitory blockade with αCTLA-4 and active co-stimulation with α4-1BB promotes rejection of B16 melanoma in the context of a suitable vaccine. In addition, we identify KLRG1 as a useful marker for monitoring the anti-tumor immune response elicited by this therapy. These findings should aid in the design of future trials for the immunotherapy of melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · cited 1×
“Also, CTLA-4 appears to support the function of the regulatory T-cell (Treg) compartment [3].”
BackgroundCurran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874 · cited 3×
“As we have observed previously for combination blockade of CTLA-4 and PD-1, we find that co-administration with an autologous tumor vaccine expressing Flt3-ligand allows these antibodies to cooperate in rejecting more than 50% of pre-implanted B16-BL6 melanomas [20].”
BackgroundMethodSelf-citationvan Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · cited 1×
“by co-administration of an autologous tumor vaccine expressing either the cytokine Granulocyte-macrophage colony-stimulating factor (GM-CSF) or FMS-like tyrosine kinase 3 ligand (Flt3ligand) [4,5].”
MethodSelf-citationPeggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967 · cited 14×
“Here, a4-1BB dampened Treg proliferation (Figure S6), reduced the Treg fraction of TIL (Figure 2), counteracted aCTLA-4’s expansion of absolute Treg numbers in the tumor (Figure S2), and decreased CTLA-4 and PD-1 expression by Tregs (Figure 5).”
BackgroundSelf-citationKrummel, M. F., & Allison, J. P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.6.2533 · Cited by 932 · cited 4×
“The co-inhibitory receptor Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) is induced on T-cells shortly after activation and functions to attenuate their proliferation, IL-2 production, and contact time with antigen presenting cells (APC) [1,2].”
BackgroundSelf-citationMonoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 898 · cited 1×
“In immunotherapy studies, 4-1BB antibodies can enhance tumor rejection, increase tumor-specific cytotoxicity, and may render effector T-cells resistant to Treg suppression [10,12,13,14,15].”
BackgroundShuford, W. W., Klussman, K., Tritchler, D. D., Loo, D. T., Chalupny, J., Siadak, A. W., Brown, T. J., Emswiler, J., Raecho, H., Larsen, C. P., et al. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.1.47 · Cited by 804
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 1×
“Combination therapy yielded highly advantageous ratios of intra-tumoral CD8+ and CD4+ effector T-cells relative to Tregs which often correlates with rejection in this system [4,16].”
BackgroundReversal of the TCR Stop Signal by CTLA-4
Schneider, H., Downey, J., Smith, A., Zinselmeyer, B. H., Rush, C., Brewer, J. M., Wei, B., Hogg, N., Garside, P., & Rudd, C. E. (2006) · Science · doi:10.1126/science.1131078 · Cited by 621 · cited 4×
“The co-inhibitory receptor Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) is induced on T-cells shortly after activation and functions to attenuate their proliferation, IL-2 production, and contact time with antigen presenting cells (APC) [1,2].”
BackgroundInfluentialSerafini, P., Carbley, R., Noonan, K. A., Tan, G., Bronte, V., & Borrello, I. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0757 · Cited by 523 · cited 1×
“GVAX has a known capacity to support the generation of MDSC even when injected on the opposite flank from tumor implantation [4,19].”
Background
Cited by
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K., & Oliveira, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00847 · Cited by 1,224
“Consistently, immunotherapy using immune checkpoint blockers (anti-CTLA-4 and/or anti-PD-1) combined with anticancer vaccines, clearly associate inhibition of tumor growth with increased proportion of IFN-γ-producing effector T cells (236, 237).”
BackgroundCancer immunotherapy: the beginning of the end of cancer?
Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,184
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Jiang, Y., Chen, M., Nie, H., & Yuan, Y. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1571892 · Cited by 640
Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 634
Self-citationMoynihan, K. D., Opel, C. F., Szeto, G. L., Tzeng, A., Zhu, E. F., Engreitz, J. M., Williams, R. T., Rakhra, K., Zhang, M. H., Rothschilds, A. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4200 · Cited by 524
Jayaprakash, P., Ai, M., Liu, A., Budhani, P., Bartkowiak, T., Sheng, J., Ager, C., Nicholas, C., Jaiswal, A. R., Sun, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96268 · Cited by 399
Self-citationCombination immunotherapy: a road map
Ott, P. A., Hodi, F. S., Kaufman, H. L., Wigginton, J. M., & Wolchok, J. D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0218-5 · Cited by 374
The promise and challenges of immune agonist antibody development in cancer
Mayes, P. A., Hance, K. W., & Hoos, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.75 · Cited by 355
Tumor infiltrating lymphocytes in ovarian cancer
Santoiemma, P. P., & Powell, D. J. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1040960 · Cited by 337
Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment
Hadrup, S., Donia, M., & thor Straten, P. (2013) · Cancer Microenvironment · doi:10.1007/s12307-012-0127-6 · Cited by 310
Spranger, S. (2016) · International Immunology · doi:10.1093/intimm/dxw014 · Cited by 290
Immunotherapy of Melanoma: Facts and Hopes
Weiss, S. A., Wolchok, J. D., & Sznol, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1550 · Cited by 281
Duraiswamy, J., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1550 · Cited by 278
Chen, S., Lee, L.-F., Fisher, T. S., Jessen, B., Elliott, M., Evering, W., Logronio, K., Tu, G. H., Tsaparikos, K., Li, X., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0118 · Cited by 277
Second- and third-generation drugs for immuno-oncology treatment—The more the better?
Dempke, W. C. M., Fenchel, K., Uciechowski, P., & Dale, S. P. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.001 · Cited by 257
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
Bartkowiak, T., & Curran, M. A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00117 · Cited by 256
Self-citationBelcaid, Z., Phallen, J. A., Zeng, J., See, A. P., Mathios, D., Gottschalk, C., Nicholas, S., Kellett, M., Ruzevick, J., Jackson, C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101764 · Cited by 244
“While the combination of anti-4-1BB and anti-CTLA-4 antibodies produced tumor rejection in these two commonly less aggressive tumor types, the same therapy failed to produce tumor growth delay in the highly aggressive B16 melanoma model [25].”
BackgroundCombinations of Immunotherapy and Radiation in Cancer Therapy
Vatner, R. E., Cooper, B. T., Vanpouille-Box, C., Demaria, S., & Formenti, S. C. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00325 · Cited by 240
“Antibody agonists to 4-1BB are also showing promise as immunotherapy, especially in combination with other immunotherapies (166, 167).”
BackgroundEnhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions
Lussier, D. M., O’Neill, L., Nieves, L. M., McAfee, M. S., Holechek, S. A., Collins, A. W., Dickman, P., Jacobsen, J., Hingorani, P., & Blattman, J. N. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000065 · Cited by 197
CAR T cell therapy: A new era for cancer treatment (Review)
Mohanty, R., Chowdhury, C., Arega, S., Sen, P., Ganguly, P., & Ganguly, N. (2019) · Oncology Reports · doi:10.3892/or.2019.7335 · Cited by 192
“Both Dr Allison and Dr Honjo encouraged the merging of various strategies to generate more advanced forms of the drug for the immune system to inhibit tumor cells more effectively (73).”
BackgroundLu, L., Xu, X., Zhang, B., Zhang, R., Ji, H., & Wang, X. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-36 · Cited by 177
“Analyzing the components of TAC from treated mice, we found that single GITR triggering slightly increased or decreased the percentages of CD4 and CD8 T cells or Treg and MDSC respectively in this tumor model, which is consistent with previous reporting effects of GITR triggering on these subsets [31,32]; although sin…”
ResultBreast Cancer and the Other Non-Coding RNAs
Dvorská, D., Braný, D., Ňachajová, M., Halašová, E., & Danková, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063280 · Cited by 38
Metadata
- Authors
- Curran, M. A., Kim, M., Montalvo, W., Al-Shamkhani, A., & Allison, J. P.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-04-29
- Volume
- 6
- Issue
- 4
- Pages
- e19499
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2070059266
- Cited by
- 213
- References
- 24
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.